DUSA Pharma (DUSA) Reports Statistically Significant Data from Kerastick Phase 2

December 14, 2012 4:00 PM EST
Get Alerts DUSA Hot Sheet
Trade DUSA Now!
Join SI Premium – FREE
DUSA Pharmaceuticals, Inc. (Nsdaq: DUSA) s reporting preliminary results of a Phase 2 clinical trial investigating the use of the Levulan® Kerastick in conjunction with BLU-U blue light illumination for the treatment of actinic keratoses (AKs) of the face and scalp when utilizing short drug incubation. The study demonstrated that treatment with Levulan Kerastick — after incubating for one, two or three hours — resulted in a statistically significant number of patients with complete lesion clearance and a statistically significant reduction in AK lesion count when compared to treatment with vehicle 12 weeks post treatment.

The multi-center, randomized, blinded, vehicle-controlled study across 13 trial sites enrolled a total of 235 subjects and followed them for up to six months. The results showed that at 12 weeks, after receiving up to 2 photodynamic therapy (PDT) treatments, subjects treated with Levulan® using incubation times of 1, 2, or 3 hours all demonstrated similar degrees of efficacy, with up to 79% AK lesion clearance rates, while subjects receiving vehicle alone had up to a 14% lesion clearance. Analysis of the 24 week follow up data showed that up to 78% of subjects treated using broad area, short drug incubation (BASDI) who were completely clear of AK lesions at 12 weeks remained free of lesions at 24 weeks. This compares to 13% of subjects treated using a spot application method.

The safety profile seen in this study is consistent with what has been seen in previous clinical studies involving Levulan® PDT and is similar to that seen in the current labeling. There were no treatment-related serious adverse events reported in the study and only one subject did not complete the study. The study utilized the Levulan® Kerastick® (aminolevulinic acid HCl) for Topical Solution, 20% with the BLU-U® Blue Light Photodynamic Therapy Illuminator which is FDA approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp.

Except for historical information, this report contains certain forward-looking statements that represent our current expectations and beliefs concerning future events, and involve certain known and unknown risk and uncertainties. These forward-looking statements relate to safety and efficacy results of the trial. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from future results, performance or achievements expressed or implied by those in the forward-looking statements made in this release. These factors include, without limitation, actions by health regulatory authorities, clinical trial risks and results, the status of our patent portfolio, reliance on third parties, and other risks and uncertainties identified in DUSA’s Form 10-K for the year ended December 31, 2011.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment